Maxim Group Maintains Buy on Health In Tech, Lowers Price Target to $3
Maxim Group analyst Allen Klee maintains Health In Tech (NASDAQ:HIT) with a Buy and lowers the price target from $4 to $3.
Read original at benzingaStocks · News reference
8-K filing — Health In Tech, Inc. (HIT)
Filed: 2026-08-13 AccNo: 0001213900-26-089165 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 13, 2026, 8:35 PM
- Checked
- Aug 13, 2026, 8:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Health In Tech Q2 2026 Earnings Call: Complete Transcript
Health In Tech (NASDAQ:HIT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
Read original at benzinga8-K filing — Health In Tech, Inc. (HIT)
Filed: 2026-08-13 AccNo: 0001213900-26-089249 Size: 268 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarHealth In Tech Affirms FY2026 Sales Guidance of $45.000M-$50.000M vs $46.813M Est
Health In Tech (NASDAQ:HIT) affirms FY2026 sales outlook from $45.000 million-$50.000 million to $45.000 million-$50.000 million vs $46.813 million estimate.
Read original at benzinga